A case of Rasmussen encephalitis treated with rituximab
- 1 August 2009
- journal article
- case report
- Published by Springer Science and Business Media LLC in Nature Reviews Neurology
- Vol. 5 (8), 458-462
- https://doi.org/10.1038/nrneurol.2009.98
Abstract
A 20-year-old woman was referred to our intensive care unit with a high frequency (every 1-2 min) of focal motor seizures. She had been diagnosed as having biopsy-proven Rasmussen encephalitis (RE) of the right hemisphere 7 years previously, since when she had been treated with numerous antiepileptic drugs, as well as with continuous immunotherapies, such as tacrolimus, corticosteroids, mycophenolate mofetil, intravenous immunoglobulin and immunoadsorption. Although hemispherectomy had been avoided due to slow progression of RE, she had not been seizure-free for more than 7 weeks since diagnosis. EEG and MRI. Focal motor status epilepticus associated with right hemispheric RE, causing continuous epileptic activity and unilateral atrophy with edema in the right hemisphere. Immunoadsorption was used initially to treat the seizures. Once they had ceased, we used 375 mg/m2 intravenous rituximab--a monoclonal anti-CD20 antibody--once-weekly for 4 weeks to stabilize the condition, leading to complete depletion of CD19+ B cells. Rituximab infusions were used again when concentrations of CD19+ B cells rose and focal seizures re-emerged. The patient remained on antiepileptic therapy (levetiracetam, oxcarbazepine, zonisamide and phenobarbital) throughout treatment.Keywords
This publication has 30 references indexed in Scilit:
- CD8+ T-cell clones dominate brain infiltrates in Rasmussen encephalitis and persist in the peripheryBrain, 2009
- B cells as therapeutic targets in autoimmune neurological disordersNature Clinical Practice Neurology, 2008
- Invited Article: Inhibition of B cell functionsNeurology, 2008
- Paraneoplastic syndromes of the CNSThe Lancet Neurology, 2008
- Astrocytes are a specific immunological target in Rasmussen's encephalitisAnnals of Neurology, 2007
- B cells move to centre stage: novel opportunities for autoimmune disease treatmentNature Reviews Drug Discovery, 2006
- Autoantibodies and Cell‐mediated Autoimmunity to NMDA‐type GluRɛ2 in Patients with Rasmussen's Encephalitis and Chronic Progressive Epilepsia Partialis ContinuaEpilepsia, 2005
- Advances in pathogenic concepts and therapeutic agents in Rasmussen’s encephalitisExpert Opinion on Investigational Drugs, 2002
- From T to B and back again: positive feedback in systemic autoimmune diseaseNature Reviews Immunology, 2001
- Rasmussen'S Encephalitis In Surgery For EpilepsyDevelopmental Medicine and Child Neurology, 1992